(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 10.09% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.89%.
Exact Sciences's revenue in 2025 is $2,939,949,000.On average, 6 Wall Street analysts forecast EXAS's revenue for 2025 to be $597,452,300,742, with the lowest EXAS revenue forecast at $595,389,669,039, and the highest EXAS revenue forecast at $599,785,658,773. On average, 7 Wall Street analysts forecast EXAS's revenue for 2026 to be $672,090,602,584, with the lowest EXAS revenue forecast at $664,150,369,791, and the highest EXAS revenue forecast at $681,457,922,827.
In 2027, EXAS is forecast to generate $756,093,763,520 in revenue, with the lowest revenue forecast at $740,996,889,731 and the highest revenue forecast at $779,890,607,690.